The PARADIGM trial: A phase III study comparing sequential therapy (ST) to concurrent chemoradiotherapy (CRT) in locally advanced head and neck cancer (LANHC).
Robert I. Haddad
Consultant or Advisory Role - Boehringer Ingelheim (U)
Research Funding - AstraZeneca
Guilherme Rabinowits
No relevant relationships to disclose
Roy B. Tishler
Honoraria - Sanofi
Douglas Adkins
No relevant relationships to disclose
Fadlo Raja Khuri
No relevant relationships to disclose
Joseph Clark
No relevant relationships to disclose
Jochen H. Lorch
No relevant relationships to disclose
Sewanti Atul Limaye
No relevant relationships to disclose
Lori J. Wirth
Honoraria - Sanofi
Anne O'Neill
No relevant relationships to disclose
Sarah Riley
No relevant relationships to disclose
Marshall R. Posner
No relevant relationships to disclose